京都大学大学院医学研究科 血液・腫瘍内科学

研究

ホーム ＞ 研究 ＞ 臨床研究グループ

臨床研究グループ

諫田 淳也（講師）、蝶名林　和久（助教）、吉永 則良（特定病院助教）、新井 康之（検査部・細胞療法センター 細胞療法科 講師）、森田　真梨（キャリア支援診療医）、恩田 佳幸（客員研究員）、下田 桜（学生）、岡 恵（移植コーディネーター）、奥田 智子（CRC）、 中根 華子（CRC）、波多江 美絵子（CRC）、相見　優（CRC）、谷村 美佳（技術補佐員）、川井 杏奈（技術補佐員）、細川 聖子（医師クラーク）、槙尾 舞（医師クラーク）

研究領域および活動内容

当研究室は、全国および京都大学関連施設との連携のもと、多施設共同臨床研究の企画・遂行、臨床データベースの整備、臨床検体の集積・保存体制の構築、ならびに造血幹細胞移植および細胞療法に関する情報管理および基盤研究を推進しています。2020年度より京都府造血幹細胞移植推進地域拠点病院として認定され、臨床・研究両面において中核的役割を担っています。

研究グループ設立とその展開

2012年には京都大学関連病院による研究ネットワーク「KHSG（Kyoto Hematology Study Group）」を、2016年には造血幹細胞移植研究に特化した「KSCTG（Kyoto Stem Cell Transplantation Group）」を設立しました。これらのグループを基盤として、悪性リンパ腫、多発性骨髄腫、白血病、造血幹細胞移植領域における介入試験およびトランスレーショナルリサーチを積極的に展開し、国内外の主要学術誌に成果を発表しています（Cytotherapy. 2025, Cell Transplant. 2023, Ann Hematol. 2023, Transplant Cell Ther. 2023, Hematology. 2022, Bone Marrow Transplant. 2022, Transplantation. 2022, Blood Adv. 2022, Sci Rep. 2020, Biol Blood Marrow Transplant. 2020, Blood Adv. 2020, Ann Hematol. 2019）。

特定臨床試験

2014年から、当院・倉敷中央病院・同志社女子大学との共同研究として、「造血器悪性腫瘍における用量調整静注ブスルファン（一日4回投与）を含む前処置を用いた同種造血幹細胞移植の有用性の検討」の臨床試験を実施し、論文化しました（Ann Hematol. 2023）。引き続き、2020年からは特定臨床研究として、ブスルファン一日1回投与について同様の多施設共同研究を実施しています（「造血器悪性腫瘍における用量調整静注ブスルファン1日1回投与を含む前処置を用いた同種造血幹細胞移植の安全性と有効性の検討」、研究責任医師：諫田）。 また、日本造血・免疫細胞療法学会主導の臨床研究「GVHD予防法に抗ヒト胸腺細胞免疫グロブリンを用いたGVH方向HLA一抗原不適合血縁者からの造血幹細胞移植療法の多施設共同第II相試験」では、諫田が主任研究者を務め、当研究室が研究事務局として研究を主導し、論文報告も行いました（Cell Transplant. 2020）。さらに、新規学会主導臨床研究「非血縁者間骨髄移植における抗ヒト胸腺細胞免疫グロブリンの無作為割付試験」についても、同様の体制で臨床試験を実施中です。

同種移植後の微小残存病変とGVHD、予後予測モデル構築

骨髄系腫瘍における移植後の微小残存病変（MRD）やGVHDに関しては、AMED研究班（2024年～2026年）において研究を進めています（研究開発課題名：同種造血幹細胞移植における微小残存病変評価とGVHD予測のためのバイオマーカーの開発・検証、および多階層データの統合解析による予後予測法の確立／研究代表者：諫田淳也）。他の血液内科の研究室とも協力しながら、多方面から移植後予後改善に向けた取り組みを行っています。また、機械学習を用いた予後予測モデルの開発にも積極的に取り組んでいます（Commun Med (Lond). 2024, Blood Adv. 2022, Blood Adv. 2019）。

同種移植におけるHLA

HLAに関する研究を積極的に進めており、現在は、HLAのエピトープ適合度が移植予後に及ぼす影響について研究を展開しています。あわせて、学会発表および論文発表も積極的に行っています（Transplantation. 2025 Feb 14., Transplant Cell Ther. 2023;29:347, Front Immunol. 2022 Mar 3;13:811733）。

血液がんゲノム

京都大学腫瘍生物学講座と共同研究を行い、変異の組み合わせやコピー数異常が予後に与える影響、genotype-phenotype relationshipについて研究を進めています。また、急性赤白血病の病態解明およびマウスモデルを用いた基礎研究により、急性赤白血病に対してルキソリチニブが奏功する可能性が示唆されたことから（Takeda J, et al. Blood Cancer Discov. 2022 Sep 6;3(5):410-427.）、そのトランスレーショナル研究として、「急性赤白血病および類似疾患に対するアザシチジン／ルキソリチニブ併用療法の安全性と有効性を検討する多施設共同非盲検無対照試験（CRB5180002）」を実施しています。 さらに、血液がんゲノム医療の開始を見据え、院内外の体制整備を進めるとともに、当学腫瘍生物学講座との共同研究として、造血器腫瘍検体の収集およびターゲットシーケンスによる遺伝子変異結果の臨床現場への還元にも日常的に取り組んでいます。各施設から送付された造血器腫瘍検体を適切に保存し、検体に紐づく臨床情報を収集するとともに、解析結果を返却する検体管理Webシステムも確立しました。ターゲットシーケンスにより同定された遺伝性白血病やその他の二次的所見については、遺伝子診療部と連携しながら結果開示や遺伝カウンセリングを実施しています。また、血液内科医に対する臨床遺伝専門医資格取得の支援も行っています。 国内初の造血器腫瘍遺伝子パネル検査として「ヘムサイト」が保険適用となったことで、造血器腫瘍に対する個別化医療の社会実装が国内で大きく進展することが期待されます。当科では、当学腫瘍生物学講座と共同で構築してきたターゲットシーケンスのシステムをヘムサイトと併用することで、より精度の高い診断、治療選択、予後予測が可能になると考えています。

院内共同研究

当院では、他科との優れた共同研究が可能である点も大きな魅力の一つです。検査部・細胞療法センター・細胞療法科、小児科、呼吸器外科、呼吸器内科、消化器内科、薬剤部、感染制御部、リハビリテーション部、栄養管理部、放射線治療部、放射線診断科、医療情報学講座・診療報酬センターなど、さまざまな部門と連携し、共同研究を推進しています。

日本造血・免疫細胞療法学会のワーキンググループ

若手医師と共に、日本造血・免疫細胞療法学会のワーキンググループ（WG）に参加し、多くの学会発表や論文報告を行い、日本の造血細胞移植医療の発展に貢献しています。成人ALL-WGとGVHD-WGでは、それぞれ新井（現在は検査部・細胞療法科 城友泰先生）および諫田がWG責任者を務めています。また、本学会として初めての産学共同研究（FLT3遺伝子変異を有するAML再発・難治性急性骨髄性白血病患者における、ギルテリチニブが同種造血幹細胞移植後成績に及ぼす影響に関する観察研究）では新井が研究代表者を、2つ目の産学共同研究（日本における同種造血幹細胞移植後GVHDのリアルワールドデータベース研究：移植登録一元管理プログラムデータベース解析研究、Transplant Cell Ther. 2024;30:907-907）では諫田が研究代表者を務めています。さらに、本邦データにとどまらず、米国（諫田・新井）および欧州（諫田）のレジストリーデータを用いた国際共同研究にも積極的に取り組んでいます（業績参照）。

国内外共同研究の推進

日本全国の多施設共同臨床試験においては、日本細胞移植研究会（JSCT）、日本成人白血病治療共同研究グループ（JALSG）、関西ミエローマフォーラム（KMF）に参画しています。さらに、欧州造血細胞移植学会（EBMT）、欧州臍帯血研究組織（Eurocord）、米国造血細胞移植学会（ASBMT）とも共同研究を推進しています。

教育・人材育成活動

臨床研究に強い関心を有する大学院生および医員に対し、研究プロジェクトへの参画機会を提供し、実践的な教育を通じた臨床研究者の育成に取り組んでいます。今後もグループ全体で、臨床研究力の向上および国際的競争力の強化を目指して、活動を継続してまいります。

最近の業績

  • Kurosawa S, Fukuda T, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Ishimaru F, Yoshimitsu M, Hino M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Arai Y; Japanese Society for Transplantation and Cellular Therapy (JSTCT). Center effect on outcomes of second allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia: a nationwide retrospective study. Cytotherapy. 2025 Mar 12:S1465-3249(25)00071-4. doi: 10.1016/j.jcyt.2025.03.002. Online ahead of print.
  • Hagino T, Ikegame K, Tanaka H, Kanda Y, Kaida K, Fukuda T, Kondo Y, Sato M, Doki N, Nakamae H, Matsuoka KI, Mori Y, Sano H, Eto T, Kawakita T, Hashii Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of Japanese Society for Transplantation, Cellular Therapy. Engraftment outcome of patients with anti-HLA antibodies in HLA-mismatched peripheral blood stem cell transplantation. Int J Hematol. 2025 Mar 20. doi: 10.1007/s12185-025-03952-y. Online ahead of print.
  • Misaki Y, Tamaki M, Yanagisawa R, Doki N, Uchida N, Tanaka M, Nishida T, Sawa M, Hasegawa Y, Ota S, Onizuka M, Mamiko SY, Katayama Y, Asada N, Kanda J, Fukuda T, Atsuta Y, Kanda Y, Yakushijin K, Nakasone H. Adverse Impact of Pre-Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation. Am J Hematol. 2025 May;100(5):821-829. doi: 10.1002/ajh.27652. Epub 2025 Mar 8.
  • Mori M, Sakai T, Oka T, Sakurada M, Iwasaki M, Takeda J, Kanda J, Nannya Y, Ogawa S, Takaori-Kondo A, Moriyoshi K, Kawabata H. Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone marrow. Br J Haematol. 2025 Feb 25. doi: 10.1111/bjh.20028. Online ahead of print.
  • Wada F, Iwasaki M, Hirayama M, Kawamura K, Kaida K, Doki N, Nakamae H, Hasegawa Y, Fukuda T, Eto T, Hiramoto N, Maruyama Y, Nagafuji K, Ota S, Ishikawa J, Ando T, Ichinohe T, Atsuta Y, Nakasone H, Kanda J. Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation.Leukemia . 2025 Apr;39(4):951-961. doi: 10.1038/s41375-025-02538-1. Epub 2025 Feb 19.
  • Iwasaki M, Kanda J, Tanaka H, Ikegame K, Shindo T, Kawase T, Yoshihara S, Doki N, Nakamae H, Eto T, Tanaka T, Ara T, Hiramoto N, Kondo Y, Matsuoka KI, Ando T, Shono K, Nagafuji K, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Morishima S. Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes. Transplantation. 2025 Feb 14. doi: 10.1097/TP.0000000000005347. Online ahead of print.
  • Itonaga H, Miyazaki Y, Kondo T, Shimazu Y, Aoki J, Kurosawa S, Ikeda T, Eto T, Uchida N, Nakazawa H, Kawamura K, Kanda J, Atsuta Y, Tachibana T. Long-Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective Study by Adult CML/MPN and MDS Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Am J Hematol. 2025 May;100(5):917-921. doi: 10.1002/ajh.27641. Epub. 2025 Feb 11.
  • Iyama S, Chi S, Idogawa M, Ikezoe T, Fukushima K, Utsu Y, Kanda J, Yoshimoto G, Kobayashi T, Hosono N, Yamauchi T, Kondo T, Nakamura Y, Kojima K, Yoshida C, Gotoh A, Yamamoto K, Kuroda J, Ishitsuka K, Sakaida E, Horiguchi H, Takada K, Ohnishi H, Kobune M, Minami Y. Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study. Ann Hematol. 2025 Jan;104(1):275-284. doi: 10.1007/s00277-025-06227-y. Epub 2025 Feb 8.
  • Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M, Mori Y, Doki N, Nishida T, Kotani T, Ogata M, Tabayashi T, Eto T, Sawa M, Imada K, Kanda J, Ichinohe T, Atsuta Y, Yanada M. HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML. EJHaem. 2025 Jan 21;6(1):e21088. doi: 10.1002/jha2.1088.eCollection. 2025 Feb.
  • Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy. Oxf Med Case Reports. 2025 Jan 18;2025(1):omae164. doi: 10.1093/omcr/omae164. eCollection 2025 Jan.
  • Tomori S, Morishima S, Kato K, Nakasone H, Nakano N, Eto T, Kawakita T, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Mori Y, Nakamae H, Nagafuji K, Uehara Y, Doki N, Kanda J, Fukuda T, Atsuta Y, Yoshimitsu M; JSTCT ATL Working Group and JSTCT Transplant Complications Working Group. Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL. Transplant Cell Ther. 2025 Apr;31(4):253.e1-253.e14. doi: 10.1016/j.jtct.2025.01.882. Epub. 2025 Jan 17.
  • Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. Increased relative eosinophil counts portend neck oedema after chimeric antigen receptor-T therapy. Br J Haematol. 2025 Feb;206(2):766-768. doi: 10.1111/bjh.19992.Epub. 2025 Jan 6.
  • Hamada R, Arai Y, Kitawaki T, Nakamura N, Murao M, Matsushita M, Miyasaka J, Asano T, Jo T, Nishikori M, Kanda J, Mizumoto C, Yamashita K, Ikeguchi R, Takaori-Kondo A. Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses.EJHaem . 2024 Nov 4;5(6):1252-1259. doi: 10.1002/jha2.1043. eCollection 2024 Dec.
  • Arai H, Hosono N, Chi S, Fukushima K, Ikeda D, Iyama S, Gotoh A, Ikezoe T, Yoshida C, Yoshimoto G, Kanda J, Takahashi N, Sakaida E, Usuki K, Yamauchi T, Minami Y. A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02. Int J Hematol. 2025 Mar;121(3):378-387. doi: 10.1007/s12185-024-03895-w. Epub 2024 Dec 16.
  • akamura N, Kanda J, Kondo T, Kitano T, Ikeda T, Imada K, Takaya R, Kubo T, Mitsuyuki S, Oka S, Yonezawa A, Takeoka T, Akasaka T, Hishizawa M, Yago K, Tsunemine H, Watanabe M, Itoh M, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Comparison of methotrexate dosing protocols for graft-versus-host disease prophylaxis after unrelated hematopoietic stem cell transplantation. Cytotherapy. 2025 Mar;27(3):307-315. doi: 10.1016/j.jcyt.2024.11.009. Epub 2024 Nov 17.
  • Shimomura Y, Kitamura T, Yanada M, Mizuno S, Kondo T, Yoshihara S, Tanaka M, Inai K, Katayama Y, Onizuka M, Fukuda T, Nakamae H, Kurokawa M, Yano S, Nara M, Masuko M, Miyakoshi S, Eto T, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Konuma T. Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission. Cytotherapy. 2025 Mar;27(3):316-323. doi: 10.1016/j.jcyt.2024.11.012. Epub 2024 Nov 17.
  • Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H. Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease. Transplant Cell Ther. 2025 Feb;31(2):103.e1-103.e13. doi: 10.1016/j.jtct.2024.11.011. Epub 2024 Nov 26.
  • Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T, Doki N, Eto T, Kawakita T, Mori Y, Takada S, Ohigashi H, Tanaka M, Kanda Y, Matsuoka KI, Ishimaru F, Atsuta Y, Kanda J, Terakura S; GVHD Working Group of the Japanese Society for Transplantation and Cellular Therapy. Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. Int J Hematol. 2025 Jan;121(1):110-125. doi: 10.1007/s12185-024-03871-4. Epub 2024 Nov 14.
  • Shimomura Y, Kitamura T, Sugita J, Terao T, Satake A, Hirakawa T, Uchida N, Shimabukuro M, Tanaka M, Eto T, Hiramoto N, Kataoka K, Nakamae H, Takase K, Kawakita T, Arai Y, Takeda W, Ishimaru F, Fukuda T, Atsuta Y, Nakasone H, Kanda J. Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy. Bone Marrow Transplant. 2024 Dec;59(12):1763-1772. doi: 10.1038/s41409-024-02424-x. Epub 2024 Sep 30.
  • Nishikubo M, Shimomura Y, Nakaya Y, Shinohara A, Uchida N, Takayama N, Kobayashi H, Uehara Y, Ishikawa J, Ishiwata K, Hiramoto N, Nakazawa H, Kataoka K, Kanda J, Nagafuji K, Kozai Y, Matsuhashi Y, Ishimaru F, Kim SW, Fukuda T, Kanda Y, Atsuta Y, Kondo E, Kako S. Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma. Bone Marrow Transplant. 2024 Dec;59(12):1735-1743. doi: 10.1038/s41409-024-02423-y. Epub 2024 Sep 25.
  • Shimazu Y, Kanda J, Takakuwa T, Onda Y, Fukushima K, Hotta M, Fuchida SI, Uoshima N, Shimura Y, Tanaka H, Ohta K, Shibayama H, Kosugi S, Yagi H, Yoshihara S, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients. Ann Hematol. 2024 Dec;103(12):5639-5649. doi: 10.1007/s00277-024-05934-2. Epub 2024 Aug 21.
  • Tamaki M, Akahoshi Y, Inamoto Y, Morita K, Uchida N, Doki N, Tanaka M, Nishida T, Ohigashi H, Nakamae H, Onizuka M, Katayama Y, Matsuoka KI, Sawa M, Ishimaru F, Kanda Y, Fukuda T, Atsuta Y, Terakura S, Kanda J. Associations between acute and chronic graft-versus-host disease. Blood Adv. 2024 Aug 27;8(16):4250-4261. doi: 10.1182/bloodadvances.2024013442.
  • Ido K, Nakamae H, Hattori N, Kanaya M, Morita K, Hino M, Ohigashi H, Fukuda T, Eto T, Nagafuji K, Hiramoto N, Maruyama Y, Ota S, Matsuoka KI, Ando T, Akasaka T, Mori Y, Kamimura T, Kawakita T, Kawamura K, Kanda J, Onizuka M, Atsuta Y, Murata M. Effect of peptide-binding motif on survival of HLA-haploidentical transplantation with post-transplant cyclophosphamide. Br J Haematol. 2024 Sep;205(3):1077-1096. doi: 10.1111/bjh.19630.
  • Kanda J, Mitsuyoshi T, Sakurai M, Nishimori H, Murata M, Uchida N, Doki N, Inamoto Y, Nishida T, Tanaka M, Katayama Y, Eto T, Matsuoka KI, Yoshihara S, Sawa M, Kawakita T, Jun G, Kurata M, Ichinohe T, Fukuda T, Teshima T, Atsuta Y, Terakura S. Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry. Transplant Cell Ther. 2024 Sep;30(9):907.e1-907.e16. doi: 10.1016/j.jtct.2024.06.023. Epub 2024 Jul 2.
  • Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N, Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H. Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT. Cytotherapy. 2024 Nov;26(11):1353-1361. doi: 10.1016/j.jcyt.2024.06.006. Epub 2024 Jun 12.
  • Kuwatsuka Y, Ito H, Tabuchi K, Konuma T, Uchida N, Inamoto Y, Inai K, Nishida T, Ikegame K, Eto T, Katayama Y, Kataoka K, Tanaka M, Takahashi S, Fukuda T, Ichinohe T, Kimura F, Kanda J, Atsuta Y, Matsuo K. Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data. Bone Marrow Transplant. 2024 Sep;59(9):1295-1301. doi: 10.1038/s41409-024-02326-y. Epub 2024 Jun 19.
  • Morishima S, Yoshimitsu M, Shindo T, Utsunomiya A, Ishida T, Ito A, Nakano N, Kawakita T, Eto T, Suehiro Y, Itonaga H, Mori Y, Miyazaki Y, Kanda J, Uchida N, Sawayama Y, Tomori S, Ichinohe T, Atsuta Y, Fukuda T, Kato K; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Individual HLAs affect survival after allogeneic stem cell transplantation in adult T-cell leukaemia/lymphoma. HLA. 2024 Jun;103(6):e15555. doi: 10.1111/tan.15555.
  • Akiyama D, Kanda J, Hanyu Y, Amagase H, Kondo T, Miyamoto T, Yasumi T, Yoshinaga N, Takaori-Kondo A. Successful Second CBT for Graft Failure After First CBT for Adult-Onset Familial Hemophagocytic Lymphohistiocytosis Type 3: A Case Report. Transplant Proc. 2024 Jun;56(5):1205-1209. doi: 10.1016/j.transproceed.2024.05.011. Epub 2024 May 29.
  • Kurosawa S, Fukuda T, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Yoshimitsu M, Ishimaru F, Sato A, Onizuka M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuch K, Atsuta Y, Arai Y; Japanese Society for Transplantation and Cellular Therapy (JSTCT). Center effect on allogeneic hematopoietic stem cell transplantation outcomes for B-cell acute lymphoblastic leukemia. Cytotherapy. 2024 Oct;26(10):1185-1192. doi: 10.1016/j.jcyt.2024.05.004. Epub 2024 May 9.
  • Terao T, Matsuoka KI, Fuji S, Kawamura S, Toya T, Doki N, Uchida N, Tanaka M, Fukuda T, Sawa M, Ishikawa J, Nishida T, Ohigashi H, Maruyama Y, Fujiwara SI, Kanda Y, Ota S, Ishimaru F, Atsuta Y, Kanda J, Ogata M, Yakushijin K, Nakasone H. Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era. Bone Marrow Transplant. 2024 Sep;59(9):1224-1231. doi: 10.1038/s41409-024-02313-3. Epub 2024 May 25.
  • Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy. Clin Exp Med. 2024 May 21;24(1):105. doi: 10.1007/s10238-024-01373-5.
  • Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8.
  • Shimazu Y, Kanda J, Suzuki K, Wada A, Kikuchi T, Ikeda T, Tsukada N, Miwa A, Itagaki M, Kako S, Nishiwaki K, Ota S, Fujiwara SI, Kataoka K, Doki N, Sawa M, Hiramoto N, Nishikawa A, Imai T, Ichinohe T, Kanda Y, Atsuta Y, Kawamura K. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. Cancer Sci. 2024 Jul;115(7):2384-2395. doi: 10.1111/cas.16198. Epub 2024 May 16.
  • Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka KI, Ikeda T, Kanda Y, Fukuda T, Kanda J, Nakamae H, Imada K, Ueda Y, Ichinohe T, Atsuta Y, Ishiyama K. Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients With Myelodysplastic Syndrome: A Nationwide Retrospective Study From Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplant Cell Ther. 2024 Jul;30(7):685.e1-685.e12. doi: 10.1016/j.jtct.2024.04.019.
  • Sugimoto M, Yonezawa A, Kanda J, Itohara K, Hira D, Yamagiwa T, Taniguchi R, Hanyu Y, Watanabe M, Arai Y, Mizumoto C, Kitawaki T, Kondo T, Yamashita K, Takaori-Kondo A, Terada T. Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis. Ther Drug Monit. 2024 Oct 1;46(5):611-618. doi: 10.1097/FTD.0000000000001198. Epub 2024 Apr 4.
  • Konuma T, Miyao K, Nakasone H, Ouchi F, Fukuda T, Tanaka M, Ozawa Y, Ota S, Kawakita T, Uchida N, Sawa M, Katayama Y, Hiramoto N, Eto T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period. Cytotherapy. 2024 Aug;26(8):910-920. doi: 10.1016/j.jcyt.2024.03.489. Epub 2024 Mar 30.
  • Nakamura N, Yamamoto N, Kondo T, Matsumoto M, Ikunari R, Sakai T, Tanaka Y, Tsunemine H, Takeda J, Kanda J, Nannya Y, Ogawa S, Takaori-Kondo A, Arima N. Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome. Int J Hematol. 2024 Jun;119(6):762-767. doi: 10.1007/s12185-024-03762-8. Epub 2024 Mar 25.
  • Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Ann Hematol. 2024 Dec;103(12):5681-5690. doi: 10.1007/s00277-024-05705-z. Epub 2024 Mar 16.
  • Kuriyama K, Fuji S, Ito A, Doki N, Katayama Y, Ohigashi H, Nishida T, Serizawa K, Eto T, Uchida N, Kanda Y, Tanaka M, Matsuoka KI, Nakazawa H, Kanda J, Fukuda T, Atsuta Y, Ogata M. Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation. Transplant Cell Ther. 2024 May;30(5):514.e1-514.e13. doi: 10.1016/j.jtct.2024.02.017. Epub 2024 Feb 18.
  • Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, Uchida N, Ishikawa J, Matsuoka KI, Yui S, Takase K, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Kako S. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024 May;59(5):630-636. doi: 10.1038/s41409-024-02229-y. Epub 2024 Feb 14.
  • Yanagisawa R, Shindo M, Shinohara A, Kuwatsuka Y, Nakase K, Kimura F, Shingai N, Nishida T, Fukuda T, Sakurai M, Kurokawa M, Koike T, Ota S, Takada S, Onizuka M, Uchida N, Tanaka M, Noguchi M, Maruyama Y, Hagihara M, Ichinohe T, Atsuta Y, Kanda J, Nakasone H, Toubai T. Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations. Transplant Proc. 2024 Mar;56(2):416-421. doi: 10.1016/j.transproceed.2024.01.049. Epub 2024 Feb 9.
  • Kurosawa S, Shimomura Y, Itonaga H, Katayama Y, Onizuka M, Tanaka M, Kobayashi H, Ozawa Y, Sawa M, Kanda J, Doki N, Fujisawa S, Uchida N, Fukuda T, Atsuta Y, Ishiyama K. Comparison of Melphalan Dose in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning. Transplant Cell Ther. 2024 May;30(5):510.e1-510.e10. doi: 10.1016/j.jtct.2024.01.083. Epub 2024 Feb 6.
  • Yanada M, Yano S, Kuwatsuka Y, Kawamura K, Fukuda T, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, Sato A, Onizuka M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Kanda J, Konuma T. The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Bone Marrow Transplant. 2024 Apr;59(4):541-549. doi: 10.1038/s41409-024-02222-5. Epub 2024 Feb 6.
  • Maeda T, Matsuda A, Kanda J, Kawabata H, Ishikawa T, Tohyama K, Kitanaka A, Araseki K, Shimbo K, Hata T, Suzuki T, Kayano H, Usuki K, Shindo-Ueda M, Arima N, Nohgawa M, Ohta A, Chiba S, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A, Mitani K; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes. Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry. Br J Haematol. 2024 May;204(5):2086-2096. doi: 10.1111/bjh.19323. Epub 2024 Jan 31.
  • Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model. Transplant Cell Ther. 2024 Apr;30(4):404-414. doi: 10.1016/j.jtct.2024.01.073. Epub 2024 Jan 26.
  • Onozawa M, Kusumoto S, Najima Y, Hashimoto H, Okada K, Tamaki M, Tanaka M, Sato T, Takahashi T, Hatano K, Onodera K, Moriuchi Y, Yakushijin K, Kanda J, Nagafuji K, Ogata M, Nakano N, Tamori A, Mizokami M. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study. Transplant Cell Ther. 2024 Mar;30(3):330.e1-330.e8. doi: 10.1016/j.jtct.2024.01.059. Epub 2024 Jan 17.
  • Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, Ara T, Eto T, Mori Y, Matsuoka KI, Kanda Y, Onizuka M, Atsuta Y, Ichinohe T, Morishima S, Kanda J; JSTCT HLA Working Group. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis. Int J Hematol. 2024 Feb;119(2):173-182. doi: 10.1007/s12185-023-03693-w. Epub 2024 Jan 17.
  • Shimomura Y, Kitamura T, Murata M, Matsuo K, Ito Y, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, Sato A, Onizuka M, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Fukuda T, Kanda J, Terakura S. Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar;30(3):326.e1-326.e14. doi: 10.1016/j.jtct.2024.01.056. Epub 2024 Jan 11.
  • Kurita N, Imahashi N, Chiba S, Tanaka M, Kobayashi H, Uchida N, Kuriyama T, Anzai N, Nawa Y, Nakano N, Ara T, Onizuka M, Katsuoka Y, Koi S, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study. Am J Hematol. 2024 Feb;99(2):236-244. doi: 10.1002/ajh.27172. Epub 2024 Jan 2.
  • Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, Katayama Y, Hiramoto N, Nakano N, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Kanda J. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Am J Hematol. 2024 Feb;99(2):263-273. doi: 10.1002/ajh.27174. Epub 2024 Jan 2.
  • Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Uehara Y, Maruyama Y, Ishiwata K, Kawakita T, Sawa M, Eto T, Ishimaru F, Kato K, Fukuda T, Atsuta Y, Kanda J, Yakushijin K, Nakasone H. Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score. Blood Adv. 2024 Mar 26;8(6):135/9-1368. doi: 10.1182/bloodadvances.2023011837.
  • Watanabe M, Konuma T, Imahashi N, Terakura S, Seo S, Morishima S, Uchida N, Doki N, Tanaka M, Nishida T, Kawakita T, Eto T, Takahashi S, Sawa M, Uehara Y, Kim SW, Ishimaru F, Ichinohe T, Fukuda T, Atsuta Y, Kanda J. Scoring system for optimal cord blood unit selection for single cord blood transplantation. Cytotherapy. 2024 Mar;26(3):286-298. doi: 10.1016/j.jcyt.2023.12.001. Epub 2023 Dec 27.
  • Jo T, Arai Y, Kitawaki T, Nakamura N, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis. Bone Marrow Transplant. 2024 Mar;59(3):419-421. doi: 10.1038/s41409-023-02175-1. Epub 2023 Dec 19.
  • Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara SI, Katayama Y, Sawa M, Serizawa K, Matsuoka KI, Uchida N, Ikeda T, Ohigashi H, Fukushima K, Hino M, Kanda Y, Fukuda T, Atsuta Y, Kanda J. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy.Cytotherapy. 2024 Feb;26(2):178-184. doi: 10.1016/j.jcyt.2023.11.012. Epub 2023 Dec 16.
  • Watanabe M, Kanda J, Volt F, Ruggeri A, Suzuki R, Rafii H, Kimura F, Cappelli B, Kondo E, Scigliuolo GM, Takahashi S, Kenzey C, Rivera-Franco MM, Okamoto S, Rocha V, Chevallier P, Sanz J, Fürst S, Cornelissen J, Milpied N, Uchida N, Sugio Y, Kimura T, Ichinohe T, Fukuda T, Mohty M, Peffault de Latour R, Atsuta Y, Gluckman E. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan. Blood Adv. 2024 Feb 13;8(3):640-652. doi: 10.1182/bloodadvances.2023010598.
  • Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, Onishi Y, Sawa M, Ozeki K, Hiramoto N, Onizuka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda J. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens. Transplant Cell Ther. 2024 Mar;30(3):318.e1-318.e11. doi: 10.1016/j.jtct.2023.12.004. Epub 2023 Dec 9.
  • Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, Ota S, Onizuka M, Hiramoto N, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Itonaga H. Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome. Am J Hematol. 2024 Feb;99(2):E42-E45. doi: 10.1002/ajh.27160. Epub 2023 Nov 15.
  • Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28.
  • Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, Sawa M, Ueda Y, Nakamae H, Nawa Y, Tanaka M, Arai Y, Ota S, Kataoka K, Nishida T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024 Feb;204(2):612-622. doi: 10.1111/bjh.19139. Epub 2023 Oct 19.
  • Konuma T, Itonaga H, Shimomura Y, Fujioka M, Aoki K, Uchida N, Onizuka M, Jinguji A, Tanaka M, Ueda Y, Katayama Y, Sawa M, Tanaka H, Nakamae H, Kawakita T, Maruyama Y, Takahashi S, Ishimaru F, Kanda J, Ichinohe T, Atsuta Y. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy. Hematol Oncol. 2024 Jan;42(1):e3217. doi: 10.1002/hon.3217. Epub 2023 Aug 18.
  • Murao M, Kondo T, Hamada R, Miyasaka J, Matsushita M, Otagaki A, Kajimoto T, Arai Y, Kanda J, Nankaku M, Ikeguchi R, Takaori-Kondo A, Matsuda S. Minimal important difference of the 6-minute walk test after allogenic hematopoietic stem cell transplantation. Disabil Rehabil. 2024 Jul;46(15):3449-3456. doi: 10.1080/09638288.2023.2246013. Epub 2023 Aug 13.